Persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: Psychometric validity (Part 5)
For PASS test responders, a large overall treatment effect was associated with an effect size of -2.95 (-3.67/1.24) and -3.22 (-3.90/1.21) for the English and French groups, respectively.
After patients switched their PPI medication at visit 2, 54% (77 of 142) in the English-speaking group and 69% (74 of 107) in the French-speaking group experienced symptom relief with esomeprazole based on their GOS response. In both linguistic groups, 32% of patients had a total resolution of their symptoms at the end of four weeks.
The response to treatment, calculated as the difference between scores at baseline and after treatment for all comparator scales, was significantly greater in patients defined as PASS test responders than in PASS test nonresponders (Figure 5). All scales in the plot show that patients had an improvement in the severity of symptoms (scored by PASS) after using esomeprazole.
Reported adverse events were mostly mild-to-moderate and transient, and none was considered to be causally related to esomeprazole therapy.
Figure 5) Difference in scores (95% CI) between Proton pump inhibitor Acid Suppression Symptom test responders and nonresponders. The solid lines indicate responses from the French-speaking group and the dashed lines indicate responses from the English-speaking group. GOS Global Overall Symptom scale; GSRS Gastrointestinal Symptom Rating Scale; OTE Overall treatment effect; QoLRAD Quality of Life in Reflux and Dyspepsia questionnaire; RDQ Reflux Disease Questionnaire Find out more about your chance to get vardenafil online pharmacy here at best online pharmacy.